Novo Nordisk (NVO)
Executive Summary Investment Thesis: Novo Nordisk represents a rare opportunity to buy a dominant healthcare franchise at a 65% discount. The GLP-1 obesity market is in early innings, yet Mr. Market is pricing in catastrophic competitive loss despite 25% revenue growth, 79% ROE, and 44% operating margins. Business Classification: Fast Grower (20%+ growth in large, expanding market) Current Valuation Assessment: Current Price: $50.26 Estimated Intrinsic Value: $90-110 Margin of Safety: 49% Recommendation: STRONG BUY Recommended Entry Zones: ...